Oxygen-Modified Fatty Acid Derivatives for NASH Fibrosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for non-alcoholic steatohepatitis (NASH) and alcoholic steatohepatitis (ASH) are inadequate in effectively addressing hepatic fibrosis and inflammation, with existing omega-3 fatty acids showing moderate efficacy and limited ability to reverse pronounced histological changes, and pre-clinical models failing to represent the full spectrum of human disease.
Innovation Solution
Administration of oxygen-containing structurally modified fatty acids, such as 2-(((5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaen-1-yl)oxy)butanoic acid (Compound A), which targets multiple aspects of NASH and ASH by reducing fibrosis and inflammation, as demonstrated in pre-clinical models through biochemical and histological assessments.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If existing omega-3 fatty acids (EPA/DHA) are used to treat NASH, then hepatosteatosis is reduced, but fibrosis and inflammation are not effectively addressed
Solution Approach 1:
The patent modifies the chemical structure of omega-3 fatty acids by introducing oxygen-containing functional groups at specific positions (hydroxyl at C-15, carbonyl at C-17) to create resolvins. This structural parameter change transforms the molecule from merely reducing steatosis to effectively addressing fibrosis and inflammation through enhanced anti-inflammatory and antifibrotic mechanisms
Solution Approach 2:
The invention creates composite functional molecules by combining omega-3 fatty acid backbones with oxygen-containing functional groups to form resolvins (RvE1, RvD1, RvD2, RvD3). These composite structures integrate multiple biological activities including anti-inflammatory, antifibrotic, and immunomodulatory effects that neither EPA/DHA alone nor simple derivatives could achieve
2Quantity of substance
If high-dose omega-3 fatty acids are administered, then plasma lipid levels are improved, but ability to reverse pronounced histological changes is limited
Solution Approach 1:
The patent changes the chemical parameters of omega-3 fatty acids by introducing oxygen-containing functional groups at specific positions, creating resolvins with enhanced biological potency. This allows the compound to effectively reverse pronounced histological changes including fibrosis and inflammation at clinically achievable doses, overcoming the limitation of high-dose requirements
3Loss of information
If pre-clinical models are used to represent human disease, then mechanistic insights are gained, but full spectrum of human disease is not represented
Solution Approach 1:
The patent develops resolvins that demonstrate multi-functional therapeutic effects across different disease manifestations. The compounds show efficacy in reducing steatosis, inflammation, and fibrosis simultaneously, and the invention encompasses multiple resolvins (RvE1, RvD1, RvD2, RvD3) with complementary activities that collectively represent the full spectrum of NASH pathology better than single-model studies could achieve
Data Source
AI summary
The present disclosure provides a compound for use in therapeutic and/or prophylactic treatment of non-alcoholic steatohepatitis (NASH) and/or alcoholic steatohepatitis (ASH). The compound for use according to the invention, is an unsaturated fatty acid with an oxygen incorporated in the β-position, and further comprising an α-substituent. More particularly, the invention provides a compound for use in treatment of NASH and/or ASH, and a method using this, wherein the compound is of Formula (II), wherein R1, R2, R3, X, and Y are as defined in the specification; and wherein this compound may be administered alone or in combination with an additional active agent.